Santen Pharmaceutical (OTCMKTS:SNPHY) Stock Price Down 5.8% – Here’s Why

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) dropped 5.8% during trading on Wednesday . The stock traded as low as $12.8955 and last traded at $12.9945. 323 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 11,785 shares. The stock had previously closed at $13.80.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold”.

Santen Pharmaceutical Stock Performance

The business’s 50-day moving average is $12.23 and its two-hundred day moving average is $11.41. The firm has a market capitalization of $4.19 billion and a price-to-earnings ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan?based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over?the?counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post?operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.